Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria~* Male or female~* Aged 18 to 60 years, inclusive~* Weighing \> 38 kg~* BMI \> 18.5 kg/m2~* HIV-1 infected~* HIV-1 RNA \<50 copies/mL~* CD4+ lymphocyte count \> 200 cells/L~* C-reactive protein \<10 mg/L~* Established on current ART regimen of boosted protease inhibitor plus 2 NRTIs for at least 3 months.~* Women must be postmenopausal, surgically sterile or practicing an effective birth control method (established before and maintained throughout the trial). Women who are not sexually active must agree to use an effective birth control method if they become heterosexually active during the trial.~* Understand the purpose of and procedures required for the study and having confirmed they are willing to participate in the study by signing the informed consent document.~Exclusion criteria (volunteers meeting any of the criteria will be excluded)~* TB (confirmed or suspected)~* Any symptoms of TB - as assessed by the WHO symptom-screening algorithm: self-reported or documented weight loss, cough, night sweats or fever.~* Clinical or laboratory evidence of significantly impaired hepatic function, or documented hepatic cirrhosis~* Clinical or laboratory evidence of acute viral hepatitis~* Co-infected with HBV or HCV.~* ALT grade 2 or higher (as defined by DAIDS grading table (ALT \>2.5 x ULN)~* DAIDS grade 3 or 4 laboratory abnormality~* Active (not clinically stabilized \>4 weeks) AIDS defining illness (Category C conditions according to the Center for Disease Control Classification System for HIV infection) with the following exceptions:~* Stable cutaneous Kaposi's Sarcoma (no internal organ involvement other than oral lesions) that is unlikely to require any form of systemic therapy during the study.~* Estimated creatinine clearance \<50 mL/min.~* Active clinically significant renal or gastro-intestinal disease.~* Any active clinically significant or life-threatening disease, medical or psychiatric condition, or findings during screening, that in the investigator's opinion would compromise the safety of the participant or the study outcome, or their ability to comply with the study procedures.~* Chronic medical requirement for any drugs that are known to affect the PK of the study drugs.~* Active drug/alcohol abuser.~* Pregnant or breastfeeding.~* Increased risks of drug side effects/hypersensitivity reactions e.g. haemophilia or history of sulfonamide allergy.~* Currently enrolled in an investigational drug study or has participated in an investigational drug study within the 4 weeks before screening.~* Unable to comply with peri-study restrictions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Standard dose DRV/r (Type: EXPERIMENTAL): Standard dose DRV/r 800/100mg without Rifampicin
- Standard DRV/r with Rifampicin (Type: EXPERIMENTAL): Rifampicin 600mg QD will be added and darunavir/ritonavir steady state pharmacokinetic analysis will be performed.
- Boosed ritonavir 200mg (Type: EXPERIMENTAL): Rifampicin 600mg QD continued with ritonavir 200mg dose doubled QD and darunavir remains 800mg QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
- Double dose DRV/r 1600/200mg QD (Type: EXPERIMENTAL): Rifampicin 600mg QD and DTG QD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
- Double dose DRV/r 800/100mg BD (Type: EXPERIMENTAL): Rifampicin 600mg QD and DTG BD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.

Based on this trial design, predict the completion outcome and termination type (if applicable).